ELI LILLY & Co (LLY) operating KPIs
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)
Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%
Eli Lilly net cash provided by / (used for) financing activities ($M) ($M)
Annual figures from Eli Lilly's filings and investor materials
Latest, FY2025
-2,213
Period ended Dec 31, 2025
Change on a year earlier
-279.9%
1,230 in FY2024
History
19 years
Since FY2007
Sources
13
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Net cash provided by / (used for) financing activities ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | -2,213 | -279.9% | Form 10-K (filed 2026-02-12) ↗ |
| FY2024 | Dec 31, 2024 | 1,230 | -64.8% | Form 10-K (filed 2026-02-12) ↗ |
| FY2023 | Dec 31, 2023 | 3,496 | -164.7% | Form 10-K (filed 2026-02-12) ↗ |
| FY2022 | Dec 31, 2022 | -5,407 | +30.9% | Form 10-K (filed 2023-02-22) ↗ |
| FY2021 | Dec 31, 2021 | -4,131 | +31.7% | Form 10-K (filed 2022-02-23) ↗ |
| FY2020 | Dec 31, 2020 | -3,137 | +35.0% | Form 10-K (filed 2021-02-17) ↗ |
| FY2019 | Dec 31, 2019 | -2,325 | -60.6% | Form 10-K (filed 2020-02-19) ↗ |
| FY2018 | Dec 31, 2018 | -5,905 | -4,240.9% | Form 10-K (filed 2019-02-19) ↗ |
| FY2017 | Dec 31, 2017 | 143 | -125.5% | Form 10-K (filed 2018-02-20) ↗ |
| FY2016 | Dec 31, 2016 | -560 | -82.0% | Form 10-K (filed 2017-02-21) ↗ |
| FY2015 | Dec 31, 2015 | -3,111 | +1,769.6% | Form 10-K (filed 2017-02-21) ↗ |
| FY2014 | Dec 31, 2014 | -166 | -95.7% | Form 10-K (filed 2017-02-21) ↗ |
| FY2013 | Dec 31, 2013 | -3,829 | -13.4% | Form 10-K (filed 2014-02-19) ↗ |
| FY2012 | Dec 31, 2012 | -4,420 | +86.5% | Form 10-K (filed 2013-02-21) ↗ |
| FY2011 | Dec 31, 2011 | -2,370 | +17.2% | Form 10-K (filed 2012-02-24) ↗ |
| FY2010 | Dec 31, 2010 | -2,022 | -63.5% | Form 10-K (filed 2011-02-22) ↗ |
| FY2009 | Dec 31, 2009 | -5,534 | -335.9% | Form 10-K (filed 2010-02-22) ↗ |
| FY2008 | Dec 31, 2008 | 2,346 | -377.7% | Form 10-K (filed 2010-02-22) ↗ |
| FY2007 | Dec 31, 2007 | -845 | – | Form 10-K (filed 2010-02-22) ↗ |
Breakdown
What makes up net cash provided by / (used for) financing activities ($m)
- Dividends paid to shareholders ($M)5,384 · FY2025
- Purchases of common stock / share repurchases ($M)4,108 · FY2025
- Issuances of long-term debt ($M)13,167 · FY2025
- Repayments of long-term debt ($M)778 · FY2025
- Net change in short-term borrowings ($M)-4,338 · FY2025
- Other financing activities, net ($M)-772 · FY2025
Cite this data
StockData. (2026). Eli Lilly Net cash provided by / (used for) financing activities ($M) ($M), annual FY2007–FY2025 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/fin_fcf_fin
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.